Is omeprazole metabolized by CYP2C19? Understanding the Genetic Link
•
4 min read
Approximately 15–20% of the Asian population are CYP2C19 poor metabolizers, a genetic variation that significantly alters how the body processes omeprazole. This critical enzyme pathway dictates an individual's response to the drug and can lead to vastly different therapeutic outcomes.
